Early pharmacodynamic evidence across three different trials in China (two in autoimmune* and one in haematological malignancies) show that in vivo mRNA CAR approaches can induce systemic CD19+ B-cell depletion across compartments (blood, LN, and/or BM), but still without sufficient numbers to determine safety, durability, and long-term clinical benefit.
* Being presented at the upcoming ASGCT conference.
Market Data 
Markets 
AI
